Loading...
XSTO
XINT
Market cap26mUSD
Jul 11, Last price  
0.38SEK
1D
-1.79%
1Q
4.35%
Jan 2017
-90.15%
IPO
-93.60%
Name

Xintela AB

Chart & Performance

D1W1MN
P/E
—
P/S
60.66
EPS
—
Div Yield, %
—
Shrs. gr., 5y
51.65%
Rev. gr., 5y
156.45%
Revenues
4m
+5,303.85%
010,028757,0003,0002,0001,628,00038,00000078,0004,215,000
Net income
-39m
L-27.54%
-2,278,496-3,007,651-11,559,000-18,060,000-21,945,000-26,274,000-43,548,000-52,924,000-58,932,000-66,217,000-54,083,000-39,190,000
CFO
-41m
L-23.37%
-3,012,000-4,149,000-9,535,000-17,402,000-14,371,000-31,205,000-30,895,000-21,330,000-42,892,000-39,489,000-53,116,000-40,704,000

Profile

Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. It is also developing XSTEM a stem cell product that is in clinical development phase for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; and EQSTEM, a stem cell product for the treatment of joint diseases in horses, as well as focuses on the preclinical development of therapeutic antibodies for aggressive cancers, including brain tumor glioblastoma and triple negative breast cancer. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.
URL
https://www.xintela.se/
IPO date
Mar 22, 2016
Employees
25
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,215
5,303.85%
78
 
Cost of revenue
43,662
59,029
76,223
Unusual Expense (Income)
NOPBT
(39,447)
(58,951)
(76,223)
NOPBT Margin
Operating Taxes
2,344
(4,284)
(6,948)
Tax Rate
NOPAT
(41,791)
(54,667)
(69,275)
Net income
(39,190)
-27.54%
(54,083)
-18.32%
(66,217)
12.36%
Dividends
Dividend yield
Proceeds from repurchase of equity
51,790
45,359
BB yield
-45.52%
-51.57%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
8,846
Net debt
(16,680)
(7,809)
(8,343)
Cash flow
Cash from operating activities
(40,704)
(53,116)
(39,489)
CAPEX
(104)
(111)
Cash from investing activities
(104)
(27,525)
Cash from financing activities
50,094
51,790
64,562
FCF
(34,484)
(51,449)
(71,470)
Balance
Cash
16,680
7,809
8,343
Long term investments
Excess cash
16,469
7,805
8,343
Stockholders' equity
(382,507)
(345,547)
(300,143)
Invested Capital
376,557
349,927
305,521
ROIC
ROCE
662.97%
EV
Common stock shares outstanding
573,299
419,869
179,671
Price
0.33
21.77%
0.27
-44.64%
0.49
-78.62%
Market cap
189,189
66.27%
113,785
29.38%
87,949
-72.69%
EV
172,509
105,976
79,606
EBITDA
(38,895)
(55,185)
(72,739)
EV/EBITDA
Interest
1,135
4,109
Interest/NOPBT